Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

被引:31
|
作者
Andrews, Louise M. [1 ]
Riva, Natalia [1 ,2 ]
de Winter, Brenda C. [1 ]
Hesselink, Dennis A. [3 ]
de Wildt, Saskia N. [4 ,5 ]
Cransberg, Karlien [6 ]
van Gelder, Teun [1 ,3 ]
机构
[1] Erasmus MC, Univ Med Ctr Rotterdam, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands
[2] Hosp Pediat JP Garrahan, Unidad Farmacocinet Clin, Buenos Aires, DF, Argentina
[3] Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC, Sophia Childrens Hosp, Intens Care, NL-3000 CA Rotterdam, Netherlands
[5] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Surg, NL-3000 CA Rotterdam, Netherlands
[6] Erasmus MC, Sophia Childrens Hosp, Div Nephrol, Dept Pediat, NL-3000 CA Rotterdam, Netherlands
关键词
algorithm; ciclosporin; dose; equation; immunosuppressive drugs; kidney; liver; mycophenolic acid; pharmacokinetics; tacrolimus; therapeutic drug monitoring; transplantation; POPULATION PHARMACOKINETIC ANALYSIS; MYCOPHENOLIC-ACID PHARMACOKINETICS; HIV-INFECTED PATIENTS; RENAL-TRANSPLANT; KIDNEY-TRANSPLANTATION; ACUTE REJECTION; CYCLOSPORINE PHARMACOKINETICS; TACROLIMUS CONCENTRATIONS; CALCINEURIN-INHIBITORS; CLINICAL PHARMACOKINETICS;
D O I
10.1517/17425255.2015.1033397
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Starting doses of tacrolimus and ciclosporin are typically chosen on a calculated mg/kg bodyweight basis. After initiation of treatment, doses are adjusted with therapeutic drug monitoring (TDM). This trial-and-error approach has been accepted by most physicians and pharmacists involved in the care of transplanted patients. Areas covered: Dosing algorithms have only fairly recently been proposed to better individualize the starting dose. This review provides an overview of all the currently available dosing algorithms in adult and children for the starting dose of ciclosporin, tacrolimus and mycophenolic acid. In these algorithms, multiple other covariates influencing the starting dose, such as age, hematocrit, comedication and genotype are taken into account. After selecting the starting dose with an algorithm and after initiation of treatment, TDM will, however, remain necessary. Whether or not implementation of such algorithms will improve clinical outcome remains to be demonstrated. Expert opinion: First of all an algorithm needs to be validated, against an independent dataset. Second, in a prospective study the algorithm should prove to reduce the time to reach the target concentration, and to reduce the number of patients with drug concentrations (far) outside the therapeutic window. Finally, a clinical trial demonstrating a benefit on clinical outcome will be crucial in achieving broad acceptance of calculating starting dose using individualized dosing algorithms.
引用
收藏
页码:921 / 936
页数:16
相关论文
共 50 条
  • [21] Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients
    Job, Kathleen M.
    Roberts, Jessica K.
    Enioutina, Elena Y.
    IIIamola, Silvia M.
    Kumar, Shaun S.
    Rashid, Jahidur
    Ward, Robert M.
    Fukuda, Tsuyoshi
    Sherbotie, Joseph
    Sherwin, Catherine M.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (07) : 747 - 765
  • [22] Drug Interactions between Antimicrobial and. Immunosuppressive Agents in Solid Organ Transplant Recipients
    Bhagat, Vikas
    Pandit, Rahul A.
    Ambapurkar, Shwetha
    Sengar, Manju
    Kulkarni, Atul P.
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2021, 25 (01) : 67 - 76
  • [23] Infectious complications of immunosuppressive medications in organ transplant recipients
    Green, Michael
    Michaels, Marian G.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (05) : 443 - 444
  • [24] The Relationship Between Weight Indices and Blood Levels of Immunosuppressive Drugs in Renal Transplant Recipients
    Badri, Shirinsadat
    Dadkhah-Tehrani, Bozorgmehr
    Atapour, Abdolamir
    Shahidi, Shahrzad
    Mortazavi, Mojgan
    Gholipourshahraki, Tahereh
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01):
  • [25] Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients
    Pennington, Catherine A.
    Park, Jeong M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (04) : 277 - 284
  • [26] Chromoblastomycosis in Solid Organ Transplant Recipients
    Raaka Kumbhakar
    Benjamin A. Miko
    Current Fungal Infection Reports, 2019, 13 : 139 - 145
  • [27] Hypertension in solid organ transplant recipients
    Zbroch, Edyta
    Malyszko, Jolanta
    Mysllwiec, Michal
    Przybylowski, Piotr
    Durlik, Magdalena
    ANNALS OF TRANSPLANTATION, 2012, 17 (01) : 100 - 107
  • [28] Melanoma in Solid Organ Transplant Recipients
    Zwald, F. O.
    Christenson, L. J.
    Billingsley, E. M.
    Zeitouni, N. C.
    Ratner, D.
    Bordeaux, J.
    Patel, M. J.
    Brown, M. D.
    Proby, C. M.
    Euvrard, S.
    Otley, C. C.
    Stasko, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1297 - 1304
  • [29] Candida in Solid Organ Transplant Recipients
    Pappas, P. G.
    Silveira, F. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : S173 - S179
  • [30] Blastomycosis in solid organ transplant recipients
    Gauthier, G. M.
    Safdar, N.
    Klein, B. S.
    Andes, D. R.
    TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (04) : 310 - 317